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Objective:Although several studies have examined the outcomes of mitral valve repair for infective endocarditis,
no studies have documented the long-term outcomes of surgical intervention for active endocarditis confined to
the mitral valve.
Methods:One hundred four patients underwent surgical intervention for active infective endocarditis confined to
the mitral valve over a 27-year period (mean age, 50 18 years; 52% female). The infected valve was native in 81
patients, previously repaired 6 patients, and prosthetic in 17 patients. Staphylococcus aureus was the most com-
monly isolated (32%) source of infection. Twenty-eight (27%) patients had annular abscesses. Surgical interven-
tion consisted of valve repair or replacement for limited infection and radical resection, annular patch
reconstruction, and valve replacement for annular abscess. Mean follow-up was 5.6  4.4 years (range, 0–20
years) and was complete.
Results: There were 9 (8.7%) in-hospital deaths and 28 (27%) late deaths. Overall survival at 5, 7, and 10 years
was 73% 5%, 68% 5%, and 58% 6%, respectively. At 7 years, freedom from recurrent endocarditis was
89% 4% and freedom from reoperation was 94% 3%. Event-free survival at 7 and 10 years was 60% 6%
and 46%  7%, respectively, and was significantly higher in patients with native endocarditis versus those with
nonnative endocarditis (ie, prosthetic or previously repaired; 7 years: 63%  7% vs 50%  12%, P< .005).
Preoperative shock, S aureus infection, and bioprosthesis insertion were independent predictors of death from
all causes. The patients in the bioprosthesis group were older (57  20 years vs 44  15 years in the mechanical
group and 46  12 years in the repair group, P ¼ .003).
Conclusions: Surgical intervention for isolated active mitral valve endocarditis remains difficult, with high mor-
bidity and mortality in the long term. Event-free survival is worse in those who have nonnative mitral valve en-
docarditis.Infective endocarditis continues to carry high mortality and
morbidity. No significant improvement has been seen in the
past 2 decades.1 Early diagnosis followed by appropriate
antibiotic therapy forms the cornerstone of treatment.2
Where medical management fails or complications of endo-
carditis ensue, timely surgical intervention is crucial for
patient survival. Surgical intervention for endocarditis can
be technically challenging because of the extensive tissue
destruction and abscess formation that can arise, and recon-
struction after radical debridement might be required.
Previously, we reported that in patients undergoing surgi-
cal intervention for endocarditis, mitral valve infection was
seen in approximately two thirds of cases, half as isolated
mitral involvement and half in conjunction with aortic in-
volvement as double-valve endocarditis.3 Although several
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for infective endocarditis as a whole,4-6 studies focusing
on mitral valve endocarditis have mainly examined the pos-
sible role of mitral valve repair.7-9 They have also been com-
pounded by including patients with other infected or
diseased valves who required concomitant operations. There
have been no studies that have documented the long-term
outcome of surgical intervention in patients who have active
infective endocarditis that is confined to the mitral valve
only.
MATERIALS AND METHODS
A review of the Toronto General Hospital cardiac surgery database re-
vealed 104 patients who had undergone surgical intervention for active iso-
lated mitral valve endocarditis from 1978 to 2004. Where necessary,
relevant information was also derived by reviewing hospital medical re-
cords. Approval was obtained from the ethics review board of the hospital.
Only patients with definite endocarditis were included, as evidenced by ap-
propriate combinations of clinical features, operative findings, histopathol-
ogy, and microbiology. Indications for surgical intervention were 1 or more
of the following: shock (n ¼ 15 [14%]), congestive cardiac failure (n ¼ 60
[58%]), cerebral embolism (n ¼ 29 [28%]), and perivalvular abscess (n ¼
28 [27%]). Table 1 shows the clinical characteristics of the patients. Our se-
ries included 2 intravenous drug abusers. There were no specific contraindi-
cations to surgical intervention, and each patient with endocarditis referred
for surgical intervention was considered on a case-by-case basis. Surgical
intervention was not offered only when it was deemed that it would not pro-
vide a substantial benefit in prognosis and quality of life.rgery c January 2009
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Infecting Organisms
Data for the infecting organism were available for 96 patients. Staphylo-
coccus aureus was the most commonly encountered and present in 33
(32%) patients; Streptococcus viridans was present in 23 (22%) patients,
Staphylococcus epidermidis was present in 9 (9%) patients, Enterococcus
faecalis was present in 1 (1%) patient, other Streptococcus species were
present in 11 (11%) patients, other bacteria were present in 11 (11%) pa-
tients, and culture-negative endocarditis was present in 8 (8%) patients.
Operative Procedures
Our principles of surgical intervention for infective endocarditis con-
sisted of uncompromising and thorough excision of all infected material
and tissues, cutting back until healthy tissues were encountered. This was
followed by appropriate reconstruction. Where infection was limited to
the leaflets of the native valve or to the prosthetic valve, valve repair or sim-
ple replacement was performed. Valve repair was our preferred option, pro-
vided adequate valve tissue was left after complete excision of infected
material. Where infection had extended to or beyond the annulus, as seen
with abscess formation, surgical intervention consisted of radical resection
of all infected tissue, followed by reconstruction as necessary with valve re-
placement, as has been previously described in detail.10-12 The choice of
prosthesis was determined by means of informed consent of the patient in
combination with the operating surgeon’s judgment. Defects in the mitral
annulus, ventricular muscle, or left atrial wall resulting from radical resec-
tion were patched with autologous or bovine pericardium.
Pre-existing mitral valve pathology was noted in 53 patients: myxoma-
tous (n ¼ 33 [33%]), rheumatic (n ¼ 8 [8%]), prosthetic dysfunction
(n¼ 10 [10%]), and ischemic (n¼ 2 [2%]). Operative data are summarized
in Table 2. One patient very early in this series had prosthetic mitral valve
endocarditis with a perivalvular leak 4 months after undergoing mitral valve
replacement. Endocarditis was not apparent at the time of surgical interven-
tion, and successful repair of the leak was undertaken. Patients in this series
had no endocarditis involvement of any other valve and did not require any
additional valve operations. Average cardiopulmonary bypass time was 93
 38 minutes, with a crossclamp time of 69  30 minutes.
All patients received intravenous antibiotics courses as per microbiology
advice, usually continuing for 4 to 6 weeks after the operation. Once fully
ambulatory and fit for discharge, patients had an in-dwelling intravenous
catheter sited and were discharged home. A home care team of community
nurses would visit the patient daily to administer the antibiotics as pre-
scribed.
Follow-up
All patients were reviewed annually by the referring cardiologist, and
data were collected prospectively. Our dedicated research personnel verified
all cardiac events and maintained a comprehensive database. The mean fol-
low-up was 5.6  4.35 years (range, 0–20 years) and was complete.
Statistics
Continuous variables were reported as mean values  standard devia-
tion. All data analyses were performed with SAS 9.1 Software (SAS Insti-
tute, Cary, NC). Fisher’s exact tests or c2 tests were used to evaluate
categorical variables univariately andwere reported as frequencies. The Stu-
dent t test was used to analyze continuous variables that had normal distri-
bution, and the Wilcoxon rank test was used for variables that had
nonparametric distribution. The Kaplan–Meier method was used to calcu-The Journal of Thoracic and Clate estimates for long-term survival, freedom from reoperation, and
event-free survival. Event-free survival was defined as the freedom from
thromboembolism (including stroke), valve thrombosis, hemolysis, struc-
tural valve dysfunction, perivalvular leak, major bleeding event, endocardi-
tis, reoperation, myocardial infarction, and death in hospital survivors. All
preoperative variables with a univariate P value of less than .25 or those
judged to be clinically important were submitted to the multivariable model
for Cox regression analysis to determine the independent predictors of op-
erative and late deaths.
RESULTS
There were 9 (8.7%) in-hospital deaths. Operative mor-
talities are summarized for the various subgroups in Table
3. Although cause of death was usually multifactorial, the
main causes were multiorgan failure (n ¼ 4), stroke (n ¼
1), septicemia (n¼ 1), respiratory failure (n¼ 1), cardiac ar-
rest (n ¼ 1), and retroperitoneal hemorrhage (n ¼ 1). Of the
TABLE 1. Clinical characteristics
Characteristic No. Percentage
Age (y) 50  18
Male sex 50 48
Comorbid conditions
Diabetes mellitus 13 13
Hypertension 15 15
Chronic obstructive lung disease 2 2
Renal failure 7 7
Recent myocardial infarction (<30 d) 3 3
Recent stroke or transient ischemic attack (<30 d) 29 28
Peripheral vascular disease 7 7
New York Heart Association class
I 6 6
II 2 2
III 10 10
IV 85 83
Preoperative rhythm
Sinus rhythm 84 81
Atrial fibrillation 20 19
Cardiogenic or septic shock 15 14
Congestive cardiac failure 60 58
Endocarditis
Native, never operated 81 78
Previous repair 6 6
Prosthetic 17 16
Previous cardiac surgery 26 25
CABG 3 3
Aortic valve replacement 2 2
Mitral valve repair 6 6
Mitral valve replacement 17 16
TV repair 2 2
Left ventricular ejection fraction
40% 83 89
<40% 10 11
Timing of operation
Elective/same hospitalization 45 51
Urgent/emergency 43 49
CABG, Coronary artery bypass grafting; TV, tricuspid valve.ardiovascular Surgery c Volume 137, Number 1 111
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erative deaths, preoperative shock was present in 5 of these
patients, preoperative renal failure was present in 4 patients,
S aureus infection was present in 7 patients, and preopera-
TABLE 2. Operative data
No.
Operation performed
Mitral valve repair 16
Mitral valve prosthesis repair 1
Mitral valve replacement 87
Mitral valve annulus reconstruction 23
Autologous pericardium 14
Bovine pericardium 9
Chordal preservation in mitral valve replacement
Posterior only 17
Anterior and posterior 12
Mitral valve prosthesis used
Mechanical 43
Bioprosthesis 44
Repair ring/band 6
Concomitant procedures
Coronary artery bypass grafting 13
Septal myectomy 2
Replacement of ascending aorta 1
TABLE 3. Operative mortalities in various subgroups
Variable No. Operative mortality (%) P value
Native endocarditis 81 7.4
Nonnative endocarditis 23 13 .41
Preoperative shock 15 33.3 .003
Preoperative renal failure 7 57.1 <.001
Preoperative stroke,
transient ischemic
attack
29 17.2 .113
Paravalvular abscess 28 10.7 .699
Staphylococcus aureus
infection
33 21 .004
Ejection fraction<40% 10 20 .24
NHYA class
I/II/III 18 0
IV 85 11 .35
Timing of operation
Elective/same
hospitalization
45 0
Urgent/emergency 43 21 <.001
Preoperative atrial
fibrillation
20 15 .37
Preoperative congestive
heart failure
60 12 .296
Preoperative syncope 6 66.67 <.001
Chordal preservation 29 13.79 .906
MV annulus
reconstruction
23 17.39 .254
NYHA, New York Heart Association; MV, mitral valve.112 The Journal of Thoracic and Cardiovascular Sutive syncope was present in 4 patients, and the operation
was performed on an urgent or emergency basis in all. Three
patients had prosthetic endocarditis. When examining for
operative mortality by surgical era, we found no difference
between the first and second halves of the study period
(1978–1994: 10.3% vs 1995–2004: 7.7%, P ¼ .73).
Mean stay in the intensive care unit was 7  20.8 days
(median, 2 days), with a mean ventilation time of 5.4 
20.3 days (median, 13 hours). Postoperative complications
are summarized in Table 4. Mean hospital stay was 17 
17 days (median, 12 days).
A further 28 patients died during follow-up. There were 9
valve-related deaths (recurrent endocarditis in 6, perivalvu-
lar leak in 1, and stroke in 2) and a further 6 cardiac deaths
(myocardial infarction in 1, congestive heart failure in 2, car-
diomyopathy in 1, and sudden death in 2). There were 13
noncardiac deaths (cancer in 4, gastrointestinal hemorrhage
unrelated to anticoagulation in 1, hepatitis in 1, renal failure
in 2, pneumonia in 2, pulmonary embolism in 1, diabetes in
1, and suicide in 1). Survival was 73%  5%, 68%  5%,
and 58% 6% at 5, 7, and 10 years, respectively (Figure 1).
Survival was similar in those undergoing surgical interven-
tion for native mitral valve endocarditis than among those
with nonnative (ie, prosthetic or previously repaired) mitral
valve endocarditis (7-year survival: 70%  6% vs 62% 
TABLE 4. Postoperative complications
Complication No.
Associated
mortality (%) P value
Reopening for bleeding 13 23 .08
Stroke 4 50 <.05
Intraoperative 3
Postoperative 1
Sternal wound infection (deep) 2 50 .17
Renal failure 4 75 <.05
Sepsis 6 50 <.01
Pulmonary complications 31 19 <.05
Insertion of permanent pacemaker 12 8.3 1.0
FIGURE 1. Long-term actuarial survival for all patients.rgery c January 2009
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ysis identified shock (hazard ratio [HR], 8.87; 95% confi-
dence interval [CI], 3.1–25.2; P < .0001), S aureus
infection (HR, 3.87; 95% CI, 1.7–8.8; P¼ .001), and tissue
mitral valve prosthesis (HR, 7.22; 95% CI, 2.7–19.6; P ¼
.0001) as independent predictors of death from all causes.
Increasing age was not a predictor of death in the model,
even when forced. Further comparison of the bioprosthesis
group with the mechanical and mitral repair groups found
age to be the only significant difference in clinical, operative,
and postoperative characteristics between the groups. Mean
age in the bioprosthesis group was 57  20 years versus 44
 15 years in the mechanical replacement group and 46 
12 years in the repair group (P ¼ .003). We were able to as-
certain septic shock (n ¼ 6) versus cardiogenic shock (n ¼
6) in 12 of 15 patients who presented with preoperative
shock. When the Cox model was recalculated with this addi-
tional information, no significant difference was found be-
tween septic and cardiogenic shock.
Recurrence of endocarditis was seen in 9 patients. All had
undergone mitral valve replacement (6 with a bioprosthesis
and 3 with a bileaflet mechanical prosthesis). Five had had
an abscess originally. Of the significant factors associated
with operative and late deaths, preoperative shock was pres-
ent in 2, syncope was present in 1, S aureus infection was
present in 5, and urgent/emergency timing was present in
4. Four had early endocarditis (1 year). The infecting or-
ganism was the same as the original episode in 4 patients
and different in 2, and in 3 patients this information was
missing because the patients were readmitted to other hospi-
tals. Two of these patients underwent reoperation and sur-
vived. Of the 7 patients managed conservatively with
antibiotic therapy, there was only 1 survivor, a young female
patient with prosthetic mitral valve endocarditis with a small
vegetation who was clinically well and responded very well
to antibiotic therapy with successful resolution of the endo-
carditis. Of the 6 endocarditis-related deaths, 1 had recur-
rence 8 years later affecting the native aortic valve,
FIGURE 2. Long-term actuarial survival for the native versus nonnative
groups.The Journal of Thoracic andwhereas the mitral valve prosthesis was unaffected, and an-
other was an intravenous drug abuser. Freedom from recur-
rent endocarditis overall was 89% 4% at 7 years and 86%
 5% at 10 years. Seven-year freedom from endocarditis
was 91%  4% for native valve endocarditic and 83% 
9% for nonnative mitral valve endocarditis (P ¼ .36).
Late morbidity events are summarized in Table 5. There
were no instances of valve thrombosis or hemolysis. There
were 11 reoperations. There were no operative mortalities
for patients undergoing reoperation, and all are alive at the
latest follow-up. Freedom from reoperation was 94% 
3% at 7 years and 84%  6% at 10 years (Figure 3). Free-
dom from reoperation was greater in the native group
compared with that in the nonnative endocarditis group,
although this did not reach statistical significance (7-year
freedom: 96%  3% and 89%  8%, respectively; P ¼
.085).
At latest follow-up, 67 patients were alive, of whom 56
were also free from reoperation and were in New York Heart
Association functional class I (n ¼ 39 [69.6%]), II (n ¼ 11
[19.6%]), or III (n¼ 6 [10.7%]). Overall event-free survival
at 7 and 10 years was 60%  6% and 46%  7%, respec-
tively (Figure 4) andwas significantly higher in the nativemi-
tral valve endocarditis group compared with that in the
nonnative group (63%  7% vs 50%  12%, P< .005;
TABLE 5. Late morbidity
Late complication No. (with consequent death)
Endocarditis recurrence 9 (6)
Thromboembolic stroke 7 (2)
Reoperations 11 (0)
Bioprosthetic structural valve
deterioration
7
Recurrent endocarditis 2
Perivalvular leak 1
Failure of repair 1
Perivalvular leak 2 (0)
Major anticoagulation-related hemorrhage 1 (0)
FIGURE 3. Long-term freedom from reoperation for all patients.Cardiovascular Surgery c Volume 137, Number 1 113
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marily a consequence of reduced valve-related morbidity and
mortality (7-year freedom from valve-related mortality and
morbidity: 76% 7% vs 61% 13, respectively; P¼ .02).
In making a comparison of outcomes of patients under-
going mitral repair with those undergoing replacement, we
examined the subgroup comprising patients whose mitral
valve was truly native (ie, unoperated; n ¼ 81) or had un-
dergone previous repair (n ¼ 6). Those with prior mitral
replacement were excluded because repair was obviously
not a surgical option for them. Sixteen of these patients
underwent repair, and 71 underwent replacement. There
was no significant survival difference in those who under-
went mitral valve repair compared with those receiving
mitral valve replacement (5-year survival: 88%  8%
vs 75%  5%, respectively; P ¼ .19). There was no dif-
ference between groups for freedom from recurrent endo-
carditis or for freedom from reoperation. Event-free
survival was improved in the mitral repair group, but
this did not achieve statistical significance (5-year event-
free survival: 91%  9% vs 78%  5%, P ¼ .25).
DISCUSSION
We have presented the early and late outcomes of surgical
intervention for active infective endocarditis confined to the
mitral valve in a cohort of patients over a 27-year period. Mi-
tral valve endocarditis carries significant mortality in the
short term (almost 9% in our series) and also in the longer
term, with a 42%mortality at 10 years. Postoperative recov-
ery is protracted; in our series mean intensive care unit stay
was 7 days, with a mean hospital stay of 17 days, and com-
plications were common. One third of late deaths were valve
related, and the incidence of recurrent endocarditis was al-
most 10% in hospital survivors.
There have been a number of studies that have examined
surgical outcomes after infective endocarditis.3-6 We pub-
lished our own series of 383 patients over a 27-year period,
in which all cases of patients with active infective endocar-
ditis undergoing surgical intervention were reviewed.3 Sur-
FIGURE 4. Event-free survival for all patients.114 The Journal of Thoracic and Cardiovascular Surgical intervention for aortic valve endocarditis was most
frequent, followed by both mitral valve and double-valve
(aortic and mitral) endocarditis. There have, to date, been
no reports on the long-term outcomes of patients undergoing
surgical intervention for isolated and active mitral valve en-
docarditis. Our current series is a subset of our original group
of 383 patients.
Gammie and coworkers4 reviewed short-term outcomes
for patients who underwent surgical intervention for native
mitral valve endocarditis. The authors identified 6627 pa-
tients from the Society of Thoracic Surgeons National Car-
diac Database during a 10-year period. Active endocarditis
was present in 40% of their series. Overall operative mor-
tality was 8.7% and was higher in the active endocarditis
group (15% vs 4% in the treated group). Our series con-
sisting solely of patients with active endocarditis carried an
operative mortality of 8.7%. In Gammie and coworkers’
series, although patients with concomitant aortic valve in-
volvement were excluded, those requiring tricuspid repair
were included, but the number for this was not given. Pa-
tients with active endocarditis were more likely to have
comorbidities (renal failure, stroke, and diabetes), more
likely to have emergency/salvage operations, and less
likely to undergo repair (16% vs 41% for the treated
group). The replacement group had a higher operative
mortality (10.8% vs 3.7% for the repair group) but also
had a higher incidence of comorbidities (preoperative renal
failure, stroke, congestive heart failure, and diabetes). Ac-
tive endocarditis, stroke within 2 weeks of surgical inter-
vention, and mitral valve replacement were independent
predictors of operative mortality on multivariable regres-
sion analysis. In our series the number of operative deaths
(n ¼ 9) was insufficient to allow multivariable analysis.
However, univariate analysis revealed that preoperative
shock, renal failure, syncope, S aureus infection, and ur-
gent/emergency operation were associated with increased
risk of operative death.
Patients with active endocarditis tend to be sicker than
those undergoing surgical intervention for healed
FIGURE 5. Event-free survival for the native versus nonnative groups.gery c January 2009
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to be encountered in active cases, prompting the need for an
early operation. This makes surgical risk greater in patients
with active endocarditis and also makes feasibility of repair
less likely.
Studies on mitral valve endocarditis have mainly focused
on the role of mitral valve repair and have included both
cases of healed and active endocarditis, as well as endocar-
ditis involving other valves. Muehrcke and associoates8
from the Cleveland Clinic reviewed 146 patients undergoing
surgical intervention for native mitral valve endocarditis, of
whom 40% had active infection and 60% were healed.
Thirty percent of their patients had endocarditis involving
other valves in addition to the mitral valve, and these re-
quired concomitant operations. Iung and colleagues7 re-
ported on 63 patients who underwent mitral valve repair
for native mitral valve endocarditis, 40% of whom had ac-
tive infection. Concomitant aortic valve endocarditis requir-
ing replacement was seen in 11 (17%) patients, and 1
required tricuspid valve repair for endocarditis. Five-year
survival and event-free survival was 96% and 62%, respec-
tively, for the active endocarditis group.
Ruttmann and coworkers9 reviewed 68 patients who un-
derwent surgical intervention for active mitral valve endo-
carditis. There was no difference in 5-year actuarial
survival between valve repair and replacement (85% vs
67%), although-event free survival at 5 years was signifi-
cantly higher in the repair group (80% vs 55%). Multivari-
able analysis demonstrated replacement and impaired left
ventricular function to be significant adverse independent
predictors of event-free survival. However, their patient pop-
ulation also did not consist of isolated mitral valve endocar-
ditis. Infective involvement of the aortic valves, tricuspid
valves, or both required concomitant aortic valve replace-
ment in 12 cases, with an additional 4 tricuspid valve proce-
dures. In our study mitral valve repair was associated with
higher event-free survival (5-year survival: 91%  9% vs
78% 5%, P¼ .25), although this was not statistically sig-
nificant and there was no difference in actuarial survival (5-
year survival: 88%  8% vs 75%  5%, P ¼ .19). These
findings should be interpreted cautiously because the num-
ber of mitral valve repairs totaled 16.
It is well established that prosthetic valve endocarditis
carries a worse outcome than native valve endocardi-
tis.3,13,14 Studies on native mitral valve endocarditis have of-
ten included cases of infection involving the previously
repaired mitral valve.4,7-9 However, a prosthesis, such as
a mitral valve ring, might be present as part of the previous
repair. The investigators of a large multicenter database on
endocarditis classed infected mitral rings as prosthetic valve
endocarditis.14 Even in the absence of a prosthesis, because
the mitral valve has previously undergone surgical interven-
tion, we would suggest that such valves are more appropri-
ately classified with prosthetic valve patients in a groupThe Journal of Thoracic andtermed ‘‘nonnative.’’ Our comparison of survival outcomes
for endocarditis of the native and therefore unoperated mitral
valve with the nonnative mitral valve (ie, previously oper-
ated, whether repaired or replaced) revealed event-free sur-
vival to be significantly improved in the native group.
Event-free survival at 7 years was almost 25% greater in
the native endocarditis group. Freedom from reoperation
and overall survival were higher in the native group, al-
though these differences did not achieve statistical signifi-
cance. The nonnative group had a greater incidence of
abscess formation (43% vs 22%, P ¼ .04), preoperative
atrial fibrillation (52% vs 10%, P< .0001), and prior coro-
nary artery bypass (13% vs 0%, P<.01) or aortic valve sur-
gery (9% vs 0%, P ¼ .047).
The presence of preoperative shock and S aureus infec-
tion as predictors of death from all causes is not surprising
and has been reported before.3,14,15 Hill and colleagues16
identified septic shock as an independent predictor of mor-
tality at 6 months in 95 patients undergoing surgical inter-
vention for definite endocarditis. In our study we did not
find type of shock (septic or cardiogenic) to be predictive
of death from all causes in the Cox regression analysis,
but our individual numbers available for this were small
(n ¼ 6 vs 6). Use of a tissue mitral valve prosthesis as a pre-
dictor of death was most likely related to these patients being
older than those who underwent mechanical valve insertion
or mitral valve repair. Although age did not emerge as an
independent predictor of death, analysis of patient charac-
teristics for the individual operative groups of repair or me-
chanical or tissue prosthesis insertion revealed age as the
only significant difference between the groups. The mean
age of patients receiving a bioprosthesis was 56.5  19.7
years, with those receiving a mechanical valve being 44.4
 15.2 years of age and those undergoing repair being
45.5  12.4 years of age (P ¼ .003, analysis of variance).
The Stanford group specifically addressed the effect of
valve choice in left-sided infective endocarditis in an anal-
ysis of 306 patients over a 32-year period.17 Isolated aortic
valve replacement was most common (62%), followed by
isolated mitral valve replacement (29%). Almost one third
of patients in their series had healed endocarditis. No sig-
nificant difference was found in either operative deaths or
late survival when comparing tissue and mechanical pros-
theses at 10 and 20 years. Increased age and prosthetic
endocarditis, among other factors, were independent pre-
dictors of operative and late death by means of multivari-
able analysis. Freedom from recurrent endocarditis and late
reoperation were not statistically different between the bi-
oprosthesis and mechanical groups. Choice of valve pros-
thesis did not emerge as an independent predictor of death
for either the operative period or for late survival. In our
current study we suspect that bioprosthesis use as a predic-
tor of late death is emerging perhaps as a surrogate for
increased age.Cardiovascular Surgery c Volume 137, Number 1 115
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nically challenging. In our series of 383 consecutive endo-
carditis patients,3 paravalvular abscess was an independent
predictor of operative mortality. We have subsequently de-
scribed the outcomes of surgical intervention for endocardi-
tis (of any valve) complicated by paravalvular abscess in 135
patients.18 High operative mortality (15.5%) was found.
Ten-year overall survival was 57%, which is, in fact, similar
to that of our current study (58%  6%). In the present se-
ries mitral paravalvular abscess was present in 28 (27%) pa-
tients and was associated with 10.7% operative mortality. It
did not emerge as an independent predictor of late death. The
relatively small number of hospital deaths precluded mean-
ingful regression analysis to examine this. In addition, it is
possible that the relatively small number of patients with
a mitral annular abscess underestimates its prognostic effect
on operative, as well as late, death.
Although operative mortality was significant (8.7%),
long-term actuarial survival (58%  6%) was favorable
when compared with that seen in other series of mitral valve
surgery. The Edinburgh Heart Valve Trial,19 one of the larg-
est randomized trials comparing mechanical with porcine bi-
oprostheses, reported 10-year actuarial survival of 53% and
47% for mechanical and tissue prostheses, respectively, in
the subgroup of patients who had isolated mitral valve re-
placement. Comparable results were reported from the US
Department of Veteran’s Administration Heart Valve trial.20
In summary, we have presented early and late outcomes of
surgical intervention for active endocarditis that is confined to
themitral valve. For a difficult and challenging condition, sat-
isfactory operative and long-term survival can be achieved.
Good long-term freedom from recurrent endocarditis and re-
peat operation are possible. Event-free survival is impaired in
those undergoing surgical intervention for nonnative mitral
valve endocarditis.
References
1. Moreillon P, Que YA. Infective endocarditis. Lancet. 2004;363:139-49.
2. Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl J Med.
2001;345:1318-30.116 The Journal of Thoracic and Cardiovascular Sur3. David TE, Gavra G, Feindel CM, Regesta T, Armstrong S, Maganti MD. Surgical
treatment of active infective endocarditis: a continued challenge. J Thorac Cardi-
ovasc Surg. 2007;133:144-9.
4. Gammie JS, O’Brien SM, Griffith BP, Peterson ED. Surgical treatment of mitral
valve endocarditis in North America. Ann Thorac Surg. 2005;80:2199-204.
5. Gillinov AM, Diaz R, Blackstone EH, Pettersson GB, Sabik JF, Lytle BW, et al.
Double valve endocarditis. Ann Thorac Surg. 2001;71:1874-9.
6. Kaiser SP, Melby SJ, Zierer A, Schuessler RB, Moon MR, Moazami N, et al.
Long-term outcomes in valve replacement surgery for infective endocarditis.
Ann Thorac Surg. 2007;83:30-5.
7. Iung B, Rousseau-Paziaud J, Cormier B, Garbarz E, Fondard O, Brochet E, et al.
Contemporary results of mitral valve repair for infective endocarditis. J Am Coll
Cardiol. 2004;43:386-92.
8. Muehrcke DD, Cosgrove DM III, Lytle BW, Taylor PC, Burgar AM,
Durnwald CP, et al. Is there an advantage to repairing infected mitral valves?
Ann Thorac Surg. 1997;63:1718-24.
9. Ruttmann E, Legit C, Poelzl G, Mueller S, Chevtchik O, Cottogni M, et al. Mitral
valve repair provides improved outcome over replacement in active infective en-
docarditis. J Thorac Cardiovasc Surg. 2005;130:765-71.
10. d’Udekem Y, David TE, Feindel CM, Armstrong S, Sun Z. Long-term results of
surgery for active infective endocarditis. Eur J Cardiothorac Surg. 1997;11:
46-52.
11. David TE, Komeda M, Brofman PR. Surgical treatment of aortic root abscess.
Circulation. 1989;80:I269-74.
12. David TE, Feindel CM, Armstrong S, Sun Z. Reconstruction of the mitral anulus.
A ten-year experience. J Thorac Cardiovasc Surg. 1995;110:1323-32.
13. Wang A, Pappas P, Anstrom KJ, Abrutyn E, Fowler VG Jr, Hoen B, et al. The use
and effect of surgical therapy for prosthetic valve infective endocarditis: a propen-
sity analysis of a multicenter, international cohort. Am Heart J. 2005;150:
1086-91.
14. Wang A, Athan E, Pappas PA, Fowler VG Jr, Olaison L, Pare C, et al. Contem-
porary clinical profile and outcome of prosthetic valve endocarditis. JAMA. 2007;
297:1354-61.
15. Miro JM, Anguera I, Cabell CH, Chen AY, Stafford JA, Corey GR, et al. Staph-
ylococcus aureus native valve infective endocarditis: report of 566 episodes from
the International Collaboration on Endocarditis Merged Database. Clin Infect Dis.
2005;41:507-14.
16. Hill EE, HerregodsMC, Vanderschueren S, Claus P, PeetermansWE, Herijgers P.
Outcome of patients requiring valve surgery during active infective endocarditis.
Ann Thorac Surg. 2008;85:1564-9.
17. Moon MR, Miller DC, Moore KA, Oyer PE, Mitchell RS, Robbins RC, et al.
Treatment of endocarditis with valve replacement: the question of tissue versus
mechanical prosthesis. Ann Thorac Surg. 2001;71:1164-71.
18. David TE, Regesta T, Gavra G, Armstrong S, Maganti MD. Surgical treatment of
paravalvular abscess: long-term results. Eur J Cardiothorac Surg. 2007;31:43-8.
19. Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian C,
Rahimtoola SH. Outcomes 15 years after valve replacement with a mechanical
versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial.
J Am Coll Cardiol. 2000;36:1152-8.
20. Oxenham H, Bloomfield P, Wheatley DJ, Lee RJ, Cunningham J, Prescott RJ,
et al. Twenty year comparison of a Bjork-Shiley mechanical heart valve with por-
cine bioprostheses. Heart. 2003;89:715-21.gery c January 2009
